Enabling Cutting-Edge Technologies That Will Help Shape Our Future
2123 Frontiers uses our research, experts, and gatherings to take a systems approach to “enable” current cutting-edge technologies in science, engineering, medicine and technology.
Defining a frontier or breakthrough is no easy feat, but at its core, we believe these are “significant” advancements with the potential to create a positive impact on humanity. Honestly, some of them will work, and many may not. Some will be quick; some will take decades. The most important thing is to have the aspiration to change the trajectory of societal impact.
We believe this magic happens at the intersection of science, medicine, business, and engineering, driven by leaders who have the boldness, resilience, and persistence to push the envelope on new frontiers and drive breakthroughs!! Our platform brings together driven entrepreneurs, innovators, pioneers, and visionaries, all with a common purpose — “enabling” breakthroughs as we collectively push society’s frontiers.
Our Frontiers
Healthcare & Life Sciences
The pace of medical innovation continues to accelerate with new ideas being pursued. Scientists are focused on several major areas of unmet need from rare diseases (Huntington’s disease, sickle cell anemia) to neurological conditions (Alzheimer's, Parkinson's, Epilepsy) to oncology (pancreatic cancer, lung cancer, colorectal cancer) and metabolic health (diabetes, obesity, hormonal conditions).
Scientists have been making significant progress on many new tools and foundational capabilities e.g. gene editing, pharmacogenomics, personalized medicine, predictive analysis, novel biomarkers, implantable/wearable devices, tissue cell engineering. These new diagnostics, devices, drugs, and software/AI will allow us to better tackle some of the most impactful diseases in medicine.
We want to enable innovators, scientists, physicians, investors and entrepreneurs to accelerate the pace of medical innovation for humanity.
High Tech
Solutions that improve data structure, data architecture models, and data related technologies such as generative AI, large language models, cloud-native data, real time data processing are foundational.
Advancement in computation such as hardware advancement (quantum computing, semiconductors), software, and algorithms (high performance computing, quantum algorithms) are enabling the processing of larger amounts of data.
Spatial computing, Augmented reality (AR), Virtual reality (VR) and mixed reality is considered the next big paradigm shift in computing, enabling human-computer interaction to take place in the real world, in and around natural bodies and physical environments.
Innovations in robotics such as soft robotics, autonomous systems, human-robot interactions, bio-inspired robotics and AI and robotics integration have wide-ranging applications in a variety of industries such as healthcare, manufacturing, education.
To enable the secure implementation of technology, advances in cybersecurity tools such as zero trust architecture, next generation cloud workforce protection, password-less authentication, blockchain, quantum computing as well as ethical and legal guidelines must be put into place.
All these innovations will contribute to transformation in every industry and bringing us closer to a reality once only imagined!
Company Spotlight: Neuropeutics
Overview: Neuropeutics has developed a first-in-class small molecule, JRMS-22, designed to prevent and reverse the aggregation of the TDP-43 protein, a pathological hallmark in over 97% of ALS cases and a significant factor in other neurodegenerative conditions. The company's unique approach harnesses a non-canonical function of the importin-ß1 (Kpnß1) protein. JRMS-22 works by interfering with Kpnß1's usual interactions, which increases its "free" levels in the cytoplasm and promotes its natural ability to act as a chaperone for misfolded proteins like TDP-43. This innovative mechanism not only reduces toxic protein clumps but also helps restore the protein to its normal location in the nucleus.
Leadership: Marc Shenouda, CEO; Janice Robertson, CSO
Financials: Raised CAD $420K in non-dilutive funding. Raising pre-seed round of CAD $1.5M led by Toronto Innovation Accelerator Partners.
Key Milestones: IND approval by 2028.
Recent Highlights: Partnership with LifeArc as of January 2025, Inaugural AbbVie Biotech Innovator Award Recipient as of May 2025, Patents published. PCT Patent: PCT/ CA2024/051313.